Lower Acetaminophen Doses Recommended Despite Cost Impact, Lack Of Data
This article was originally published in The Tan Sheet
Executive Summary
A joint advisory committee recommended as a "top priority" that FDA lower the maximum single and daily dose of acetaminophen, despite inconclusive data that the current dose poses significant hepatotoxicity risks
You may also be interested in...
Pediatric OTC Cough/Cold Rulemaking Absent From FDA Regulatory Agenda
The Spring 2015 unified agenda lists June for a final rule on deeming electronic cigarettes and other alternatives to traditional cigarettes and smokeless tobacco products subject to FDA regulation. FDA adds an item to create a single set of regulations on fixed-combination Rx and OTC drugs.
Pediatric OTC Cough/Cold Rulemaking Absent From FDA Regulatory Agenda
The Spring 2015 unified agenda lists June for a final rule on deeming electronic cigarettes and other alternatives to traditional cigarettes and smokeless tobacco products subject to FDA regulation. FDA adds an item to create a single set of regulations on fixed-combination Rx and OTC drugs.
FDA Targets Acetaminophen Safety Evaluation In Plan To Mine OTC Use Data
An RFP to provide FDA with direct access to data on consumers’ OTC use identifies the public health impact of potential changes in dosing information on acetaminophen product labels as one reason for the planned data evaluation. Access to the data also will increase FDA’s ability to perform regulatory impact studies, particularly to assess the impact of Rx-to-OTC switches.